share_log

Tracon Pharmaceuticals | 8-K: TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Tracon Pharmaceuticals | 8-K: TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Tracon Pharmaceuticals | 8-K:TRACON Pharmicals公佈2024年第一季度財務業績並提供公司最新情況
美股SEC公告 ·  05/15 04:34

Moomoo AI 已提取核心訊息

On May 14, 2024, Tracon Pharmaceuticals, Inc. released its financial results for the first quarter ending March 31, 2024. The company reported a decrease in research and development expenses to $1.9 million from $5.0 million in the same period the previous year, attributed to the completion of enrollment for the ENVASARC Phase 2 pivotal trial. General and administrative expenses also decreased to $1.4 million from $2.3 million. The net loss for the quarter was $3.2 million, a significant reduction from the $8.5 million loss in the first quarter of 2023. Cash, cash equivalents, and restricted cash totaled $8.0 million, expected to fund operations into late Q3 2024. Tracon also highlighted the progress of its ENVASARC trial, with final response data expected in Q3 2024. Additionally, the company has been granted an extension by the Nasdaq Hearings Panel to meet listing requirements by June 3, 2024, and has executed a reverse stock split and filed an S-1 as part of this compliance process.
On May 14, 2024, Tracon Pharmaceuticals, Inc. released its financial results for the first quarter ending March 31, 2024. The company reported a decrease in research and development expenses to $1.9 million from $5.0 million in the same period the previous year, attributed to the completion of enrollment for the ENVASARC Phase 2 pivotal trial. General and administrative expenses also decreased to $1.4 million from $2.3 million. The net loss for the quarter was $3.2 million, a significant reduction from the $8.5 million loss in the first quarter of 2023. Cash, cash equivalents, and restricted cash totaled $8.0 million, expected to fund operations into late Q3 2024. Tracon also highlighted the progress of its ENVASARC trial, with final response data expected in Q3 2024. Additionally, the company has been granted an extension by the Nasdaq Hearings Panel to meet listing requirements by June 3, 2024, and has executed a reverse stock split and filed an S-1 as part of this compliance process.
2024年5月14日,Tracon Pharmicals, Inc.發佈了截至2024年3月31日的第一季度財務業績。該公司報告稱,研發費用從去年同期的500萬美元減少至190萬美元,這要歸因於ENVASARC第二階段關鍵試驗的註冊完成。一般和管理費用也從230萬美元降至140萬美元。該季度的淨虧損爲320萬美元,較2023年第一季度的850萬美元虧損大幅減少。現金、現金等價物和限制性現金總額爲800萬美元,預計將爲2024年第三季度末的運營提供資金。Tracon還強調了其ENVASARC試驗的進展,最終的響應數據預計將在2024年第三季度公佈。此外,納斯達克聽證會小組已批准該公司延期,以在2024年6月3日之前滿足上市要求,並已執行反向股票拆分並提交了S-1作爲合規程序的一部分。
2024年5月14日,Tracon Pharmicals, Inc.發佈了截至2024年3月31日的第一季度財務業績。該公司報告稱,研發費用從去年同期的500萬美元減少至190萬美元,這要歸因於ENVASARC第二階段關鍵試驗的註冊完成。一般和管理費用也從230萬美元降至140萬美元。該季度的淨虧損爲320萬美元,較2023年第一季度的850萬美元虧損大幅減少。現金、現金等價物和限制性現金總額爲800萬美元,預計將爲2024年第三季度末的運營提供資金。Tracon還強調了其ENVASARC試驗的進展,最終的響應數據預計將在2024年第三季度公佈。此外,納斯達克聽證會小組已批准該公司延期,以在2024年6月3日之前滿足上市要求,並已執行反向股票拆分並提交了S-1作爲合規程序的一部分。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息